Idexx Laboratories (IDXX) Common Equity (2009 - 2026)

Idexx Laboratories has reported Common Equity for 18 years, with the latest figure at $1.6 billion in Q2 2026.

• On a quarterly basis, Common Equity rose 10.54% year-over-year to $1.6 billion in Q2 2026; TTM through Jun 2026 was $1.6 billion, a 10.54% increase from a year earlier, with the FY2025 full-year figure at $1.6 billion, up 0.63% from the prior year.
• Common Equity was $1.6 billion for Q2 2026 at Idexx Laboratories, up from $1.6 billion in the prior quarter.
• The five-year high for Common Equity was $1.6 billion in Q3 2024, with the low at $457.0 million in Q2 2022.
• Average Common Equity over 5 years is $1.3 billion, with a median of $1.5 billion recorded in 2023.
• The sharpest annual moves came in 2022 and 2023: Common Equity tumbled 38.92% in 2022, then surged 172.57% in 2023.
• Over 5 years, Common Equity stood at $608.7 million in 2022, then soared by 143.87% to $1.5 billion in 2023, then grew by 7.46% to $1.6 billion in 2024, then gained by 0.63% to $1.6 billion in 2025, then climbed by 0.45% to $1.6 billion in 2026.
• The last three Common Equity figures came in at $1.6 billion (Q2 2026), $1.6 billion (Q1 2026), and $1.6 billion (Q4 2025), per Business Quant data.